Articles related to IMMUNOTHERAPY

Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.

The rapid exhaustion of T cells upon encountering a tumor, as revealed in a recent study, challenges existing theories and may have profound implications for cancer immunotherapies. Explore the findings to understand how this discovery could influence the future of personalized treatment.

This phase 2 trial demonstrates the potential of perioperative nivolumab combined with chemotherapy in achieving higher pathological complete response and survival rates in stage III NSCLC. Explore the detailed findings to understand how this approach may influence future treatment paradigms.

The KEYNOTE-789 study results have sparked a debate on the role of immunotherapy in treating stage IV EGFR-mutated NSCLC. While the study did not show a significant benefit of adding pembrolizumab to chemotherapy, experts agree that the potential role of immunotherapy, particularly in combination with anti-angiogenic therapy, should not be completely dismissed.

Researchers at Roswell Park Comprehensive Cancer Center have unveiled a novel approach using bispecific T-cell engagers (BiTEs) to enhance immune responses against ovarian cancer. This promising pathway may lead to improved therapeutic options for patients unresponsive to conventional immunotherapies.

The discovery of lactate’s potential to rejuvenate immune cells and combat cancer opens up exciting new avenues in the field of immunotherapy. Dive in to uncover how a simple metabolic byproduct could drastically reshape cancer treatment strategies.